Affluent Medical SA (FR:CVX)
:CVX
Want to see FR:CVX full AI Analyst Report?
Top Page
Affluent Medical SA
(CVX)
Select Model
Select Model
Rating:50Neutral
Price Target:
€3.50
▲(16.28% Upside)
Action:Reiterated
Date:06/17/26
The score is held down primarily by weak financial performance (zero 2025 revenue, widening losses, persistent cash burn, and rising leverage from falling equity). Technicals provide a partial offset as the stock is trading above key moving averages with positive momentum, while valuation remains unfavorable due to a negative P/E and no dividend yield data.
Positive Factors
Diversified clinical pipeline
Affluent Medical's portfolio spans structural heart, endovascular aneurysm sealing, and urinary incontinence devices. A multi-indication pipeline reduces reliance on a single program, spreads clinical and regulatory risk, and supports multiple potential commercialization pathways over the next 2–6 months to years.
Negative Factors
Zero 2025 revenue and wider losses
Reporting zero revenue in 2025 after prior scaling and materially wider net losses signals a major setback in commercial traction or milestone recognition. Persistently absent top-line inflows undermine self-funded R&D and increase reliance on external financing, constraining long-term program delivery.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified clinical pipeline
Affluent Medical's portfolio spans structural heart, endovascular aneurysm sealing, and urinary incontinence devices. A multi-indication pipeline reduces reliance on a single program, spreads clinical and regulatory risk, and supports multiple potential commercialization pathways over the next 2–6 months to years.
Read all positive factors
Affluent Medical SA (CVX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€209.64M
Dividend YieldN/A
Average Volume (3M)9.49K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue Growth-100.00%
EPS Growth-50.15%
CountryFR
Employees66
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.64
Shares Outstanding59,243,675
10 Day Avg. Volume9,769
30 Day Avg. Volume9,492
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)12.26
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.00Price Target Upside66.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€1.38M
Affluent Medical SA Business Overview & Revenue Model
Company Description
Carvolix S.A. operates as a medical technology firm, concurrently involved in both commercialization and clinical development, specializing in treatment solutions for structural heart ailments and cerebral strokes. The company's innovative endeavo...
How the Company Makes Money
As a development-stage medtech company, Affluent Medical’s business model is primarily based on advancing its device candidates through R&D, preclinical and clinical studies, and regulatory pathways with the aim of future commercialization. Public...
Affluent Medical SA Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 4.12M | 1.22M | 1.34M | 1.45M |
| Gross Profit | -2.19M | -9.27M | -1.20M | -1.10M | -1.29M |
| EBITDA | -15.81M | -13.44M | -13.34M | -13.21M | -10.89M |
| Net Income | -24.97M | -14.74M | -15.65M | -15.23M | -14.82M |
Balance Sheet | |||||
| Total Assets | 47.83M | 60.86M | 56.62M | 60.02M | 70.03M |
| Cash, Cash Equivalents and Short-Term Investments | 1.76M | 6.62M | 1.66M | 2.58M | 11.41M |
| Total Debt | 24.04M | 16.33M | 17.13M | 17.73M | 19.75M |
| Total Liabilities | 42.28M | 30.59M | 25.15M | 26.19M | 26.50M |
| Stockholders Equity | 5.55M | 30.27M | 31.47M | 33.83M | 43.53M |
Cash Flow | |||||
| Free Cash Flow | -11.72M | -11.47M | -12.24M | -11.23M | -12.70M |
| Operating Cash Flow | -11.61M | -11.32M | -12.05M | -11.08M | -12.36M |
| Investing Cash Flow | 5.25M | -480.00K | -184.00K | -146.00K | -160.00K |
| Financing Cash Flow | 6.88M | 11.37M | 11.32M | 2.40M | 18.28M |
Affluent Medical SA Technical Analysis
Positive
3.01
Price Trends
3.19
Positive
3.23
Positive
2.40
Positive
Market Momentum
0.11
Negative
57.60
Neutral
58.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:CVX, the sentiment is Positive. The current price of 3.01 is below the 20-day moving average (MA) of 3.38, below the 50-day MA of 3.19, and above the 200-day MA of 2.40, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 57.60 is Neutral, neither overbought nor oversold. The STOCH value of 58.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:CVX.
Affluent Medical SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €249.43M | -5.51 | 59.08% | ― | 1.79% | 15.89% | |
50 Neutral | €209.64M | -5.67 | -57.39% | ― | -100.00% | -50.15% | |
48 Neutral | €29.51M | 2.58 | ― | ― | 7.43% | ― | |
46 Neutral | €51.16M | -7.67 | 467.60% | ― | 42.86% | 13.93% | |
45 Neutral | €26.61M | -6.94 | -450.14% | ― | 32.62% | 7.10% |
* Healthcare Sector Average
FR:CVX
Affluent Medical SA
3.54
2.18
160.29%
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.15
0.03
26.45%
FR:ALTHE
Theraclion SA
0.70
0.36
105.88%
FR:ALDMS
Diagnostic Medical Systems
1.27
0.06
4.96%
FR:ALMDT
Median Technologies
5.13
3.81
287.46%
FR:ALIMP
Implanet SA
0.19
0.09
92.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.